CERENO SCIENTIFIC AB B Total Liabilities
CERENO SCIENTIFIC AB B total liabilities. Based on the latest financial reports, CERENO SCIENTIFIC AB B (4A1) has total liabilities worth €261.12 Million EUR (≈ $305.28 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See 4A1 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Total Liabilities of CERENO SCIENTIFIC AB B (2021–2025)
Total liabilities of CERENO SCIENTIFIC AB B from 2021 to 2025. This chart illustrates how CERENO SCIENTIFIC AB B's total liabilities have evolved over time, based on quarterly financial data.
CERENO SCIENTIFIC AB B Competitors by Total Liabilities
The table below lists competitors of CERENO SCIENTIFIC AB B ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gold Pacific Co. Ltd
KQ:038530
|
Korea | ₩8.14 Billion |
|
Semyung Electric Machinery Co.Ltd
KQ:017510
|
Korea | ₩20.49 Billion |
|
NeueHealth Inc
NYSE:NEUE
|
USA | $1.14 Billion |
|
Queenco-L
TA:QNCO
|
Israel | ILA83.55 Million |
|
Thermaltake Technology Co Ltd
TWO:3540
|
Taiwan | NT$4.03 Billion |
|
Arn Media Ltd
AU:A1N
|
Australia | AU$532.99 Million |
|
Alkim Alkali Kimya AS
IS:ALKIM
|
Turkey | TL1.41 Billion |
|
Guillemot Corporation S.A.
PA:GUI
|
France | €59.05 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down CERENO SCIENTIFIC AB B's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of CERENO SCIENTIFIC AB B.
Liquidity & Leverage Metrics
CERENO SCIENTIFIC AB B Total Liabilities Ratios Explained
CERENO SCIENTIFIC AB B total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CERENO SCIENTIFIC AB B's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CERENO SCIENTIFIC AB B (2021–2025)
The table below shows the annual total liabilities of CERENO SCIENTIFIC AB B from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €150.08 Million ≈ $175.46 Million |
-32.35% |
| 2024-12-31 | €221.85 Million ≈ $259.36 Million |
+223.57% |
| 2023-12-31 | €68.56 Million ≈ $80.16 Million |
+384.80% |
| 2022-12-31 | €14.14 Million ≈ $16.53 Million |
+32.50% |
| 2021-12-31 | €10.67 Million ≈ $12.48 Million |
-- |
About CERENO SCIENTIFIC AB B
Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden. The company's lead drug candidate is CS1, a HDACi, proprietary reformulation of VPA that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as a… Read more